Literature DB >> 23838536

Beyond the basics: the differential effects of demographics and hepatitis status on treatment outcome in hepatocellular carcinoma.

Ahmed O Kaseb.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23838536     DOI： 10.1159/000352005

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


× No keyword cloud information.
  2 in total

1.  Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Michiko Iwasaki; Humaid O Al-Shamsi; Kanwal Pratap Singh Raghav; Lauren Girard; Sheree Cheung; Van Nguyen; Khaled M Elsayes; Lianchun Xiao; Reham Abdel-Wahab; Ahmed S Shalaby; Manal Hassan; Hesham M Hassabo; Robert A Wolff; James C Yao
Journal:  Onco Targets Ther       Date:  2016-02-15       Impact factor: 4.147

2.  Welcome to Journal of Hepatocellular Carcinoma.

Authors:  Ahmed O Kaseb
Journal:  J Hepatocell Carcinoma       Date:  2015-01-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.